In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

(2019) George G. Zhanel et al.   DRUGS

A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia

(2019) Marya D. Zilberberg et al.   CHEST

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

(2019) Patrice Nordmann et al.   CLINICAL INFECTIOUS DISEASES

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

(2019) Yohei Doi   CLINICAL INFECTIOUS DISEASES

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

(2018) Islam M. Ghazi et al.   PHARMACOLOGY

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

(2018) Michael R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Stability of cefiderocol against clinically significant broad-spectrum oxacillinases

(2018) Laurent Poirel et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients

(2018) Kenneth V I Rolston et al.   Open Forum Infectious Diseases

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015

(2018) Masakatsu Tsuji et al.   Open Forum Infectious Diseases

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

(2017) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015

(2017) Masakatsu Tsuji et al.   Open Forum Infectious Diseases

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016

(2017) Masakatsu Tsuji et al.   Open Forum Infectious Diseases

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antibacterial Activity of S-649266 against Gram-negative Clinical Strains Collected in North America and Europe, 2015

(2016) Meredith Hackel et al.   Open Forum Infectious Diseases

Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options

(2015) Ya-Ting Chang et al.   Frontiers in Microbiology

Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen

(2012) J. S. Brooke   CLINICAL MICROBIOLOGY REVIEWS

Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results

(2012) R. Girardello et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Stenotrophomonas maltophilia: an emerging opportunist human pathogen

(2009) W John Looney et al.   LANCET INFECTIOUS DISEASES